What Is Semaglutide?

Semaglutide is a GLP-1 receptor agonist — a class of drug that mimics the action of glucagon-like peptide-1, a hormone involved in regulating blood sugar and appetite. It was originally developed for the management of type 2 diabetes and has since been studied and approved in higher doses for chronic weight management in adults with obesity or weight-related health conditions.

Semaglutide works primarily by slowing gastric emptying, reducing appetite, and increasing feelings of fullness after eating. It is administered by subcutaneous injection, typically once weekly, though oral formulations also exist. Brand names include Ozempic (diabetes indication) and Wegovy (weight management indication).

In clinical trials, semaglutide has demonstrated significant reductions in body weight compared to placebo. It is one of the most studied GLP-1 agonists currently available and has regulatory approval in the UK, US, and EU for specific indications. However, it is a prescription medicine and should only be used under licensed clinician supervision following proper medical assessment.

Clinics offering semaglutide vary considerably in how they structure access. Some operate full concierge medicine models with GP oversight and regular monitoring. Others offer more streamlined online prescribing pathways. When comparing providers, ask about the assessment process, what monitoring is included, how side effects are managed, and whether a licensed prescriber is directly involved.

Common side effects include nausea, vomiting, diarrhoea, and constipation, particularly during dose escalation. More serious but rare risks include pancreatitis and thyroid concerns. Semaglutide is not appropriate for everyone and requires individual clinical assessment.

This page is informational only. Peptide Clinic Finder does not prescribe or sell semaglutide. Use this directory to compare clinic listings and send enquiries to providers who offer supervised semaglutide programmes.